Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Clin Epigenetics ; 13(1): 33, 2021 02 11.
Article in English | MEDLINE | ID: mdl-33573703

ABSTRACT

BACKGROUND: Although R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) remains the standard chemotherapy regimen for diffuse large B cell lymphoma (DLBCL) patients, not all patients are responsive to the scheme, and there is no effective method to predict treatment response. METHODS: We utilized 5hmC-Seal to generate genome-wide 5hmC profiles in plasma cell-free DNA (cfDNA) from 86 DLBCL patients before they received R-CHOP chemotherapy. To investigate the correlation between 5hmC modifications and curative effectiveness, we separated patients into training (n = 56) and validation (n = 30) cohorts and developed a 5hmC-based logistic regression model from the training cohort to predict the treatment response in the validation cohort. RESULTS: In this study, we identified thirteen 5hmC markers associated with treatment response. The prediction performance of the logistic regression model, achieving 0.82 sensitivity and 0.75 specificity (AUC = 0.78), was superior to existing clinical indicators, such as LDH and stage. CONCLUSIONS: Our findings suggest that the 5hmC modifications in cfDNA at the time before R-CHOP treatment are associated with treatment response and that 5hmC-Seal may potentially serve as a clinical-applicable, minimally invasive approach to predict R-CHOP treatment response for DLBCL patients.


Subject(s)
5-Methylcytosine/analogs & derivatives , Antineoplastic Combined Chemotherapy Protocols/metabolism , Cell-Free Nucleic Acids/metabolism , Lymphoma, Large B-Cell, Diffuse/drug therapy , 5-Methylcytosine/blood , 5-Methylcytosine/metabolism , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Biomarkers, Pharmacological/metabolism , Cohort Studies , Cyclophosphamide/metabolism , Cyclophosphamide/therapeutic use , DNA Demethylation/drug effects , Doxorubicin/metabolism , Doxorubicin/therapeutic use , Female , Humans , Logistic Models , Lymphoma, Large B-Cell, Diffuse/diagnosis , Lymphoma, Large B-Cell, Diffuse/metabolism , Male , Middle Aged , Predictive Value of Tests , Prednisone/metabolism , Prednisone/therapeutic use , Rituximab/metabolism , Rituximab/therapeutic use , Sensitivity and Specificity , Vincristine/metabolism , Vincristine/therapeutic use
2.
Macromol Biosci ; 21(4): e2000382, 2021 04.
Article in English | MEDLINE | ID: mdl-33522144

ABSTRACT

Host defense systems can invade viral infection through immune responses and cellular metabolism. Recently, many studies have shown that cellular metabolism can be reprogrammed through N6 -methyladenosine (m6 A) modifications during viral infection. Among of them, methyltransferase like-14 enzyme (METTL14) plays an important role in m6 A RNA modification, yet its antiviral function still remains unclear. In this work, it is uncovered that metal-protein nanoparticles designated GSTP1-MT3(Fe2+ ) (MPNP) can polarize macrophages toward the M1 phenotype and activate immune responses to induce Interferon-beta (IFN-ß) production in vesicular stomatitis virus (VSV)-infected macrophages. Further investigation elucidates that a high dose of IFN-ß can promote the expression of METTL14, which has a well anti-VSV capacity. Moreover, it is found that other negative-sense single-stranded RNA viruses, such as influenza viruses (H1N1(WSN)), can also be inhibited through either immune responses or METTL14. Collectively, these findings provide insights into the antiviral function of METTL14 and suggest that the manipulation of METTL14 may be a potential strategy to intervene with other negative-sense single-stranded RNA viruses infections.


Subject(s)
Antiviral Agents/pharmacology , Immunity, Innate/drug effects , Influenza A Virus, H1N1 Subtype , Metal Nanoparticles/chemistry , Nanocomposites/chemistry , Animals , Cell Line , Gene Expression/drug effects , HEK293 Cells , Humans , Interferon-beta/genetics , Iron/chemistry , Methyltransferases/metabolism , Mice , Nanoparticles , Phenotype , RAW 264.7 Cells , THP-1 Cells , Vesicular stomatitis Indiana virus/metabolism , Vesiculovirus , Virus Replication/drug effects
3.
Front Cell Dev Biol ; 9: 781267, 2021.
Article in English | MEDLINE | ID: mdl-35071229

ABSTRACT

Background: The symptoms of coronavirus disease 2019 (COVID-19) range from moderate to critical conditions, leading to death in some patients, and the early warning indicators of the COVID-19 progression and the occurrence of its serious complications such as myocardial injury are limited. Methods: We carried out a multi-center, prospective cohort study in three hospitals in Wuhan. Genome-wide 5-hydroxymethylcytosine (5hmC) profiles in plasma cell-free DNA (cfDNA) was used to identify risk factors for COVID-19 pneumonia and develop a machine learning model using samples from 53 healthy volunteers, 66 patients with moderate COVID-19, 99 patients with severe COVID-19, and 38 patients with critical COVID-19. Results: Our warning model demonstrated that an area under the curve (AUC) for 5hmC warning moderate patients developed into severe status was 0.81 (95% CI 0.77-0.85) and for severe patients developed into critical status was 0.92 (95% CI 0.89-0.96). We further built a warning model on patients with and without myocardial injury with the AUC of 0.89 (95% CI 0.84-0.95). Conclusion: This is the first study showing the utility of 5hmC as an accurate early warning marker for disease progression and myocardial injury in patients with COVID-19. Our results show that phosphodiesterase 4D and ten-eleven translocation 2 may be important markers in the progression of COVID-19 disease.

SELECTION OF CITATIONS
SEARCH DETAIL
...